Our pathway to net zero impact on climate

We’re committed to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

This document gives more detail on the pathway we have set to a net zero impact on climate, although there are many interdependencies with our nature goals.
# Our climate targets

We have set a clear pathway to a net zero impact on climate. By 2030, we aim to reduce carbon emissions by 80% with the remainder covered through investment in high-quality nature-based solutions, and by 2045, we aim to be at the Science Based Target Initiative Net Zero Standard, with carbon emissions reduced by at least 90% and the remainder tackled through high-quality carbon credits.

<table>
<thead>
<tr>
<th>Year</th>
<th>Target Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2025</td>
<td>100% imported renewable electricity by 2025 and 100% renewable electricity (imported and generated) by 2030 (Scope 2)</td>
</tr>
<tr>
<td>2030</td>
<td>80% absolute reduction in greenhouse gas emissions(^1) from a 2020 baseline, across all scopes(^2) and investment in nature-based solutions for the remaining 20% of our footprint by 2030</td>
</tr>
<tr>
<td>2045</td>
<td>Net zero greenhouse gas emissions across our full value chain by 2045: 90% absolute reduction in emissions from a 2020 baseline, across all scopes and all residual emissions neutralised</td>
</tr>
</tbody>
</table>

1. Previously stated as net zero by 2030
2. This is a new longer-term target, aligned to the SBTi Net-Zero Standard definition of net zero

- Our net zero targets cover the full value chain of emissions reductions, from a baseline of 2020.
- Our net zero targets have been approved by the Science Based Target Initiative’s Corporate Net-Zero Standard, the world’s only framework for corporate net-zero target setting in line with climate science.
- We disclose progress against these targets annually in our Annual Report and ESG Performance Report.
Our value chain carbon footprint

We have mapped our carbon footprint across our value chain to ensure we have a clear understanding of where to focus our efforts, which informs our pathway to net zero.

Supply chain
Scope 3 emissions from the goods and services that GSK buys from other companies and other upstream emissions.

- Purchased goods: 1.6m tonnes CO₂e per annum
- Purchased services: 0.9m tonnes CO₂e per annum
- Capital investments: 0.2m tonnes CO₂e per annum
- Commuting: 0.066m tonnes CO₂e per annum
- Business travel: 0.09m tonnes CO₂e per annum
- Upstream energy: 0.1m tonnes CO₂e per annum

GSK’s operations
Scope 1 and 2 emissions from running our labs, factories and commercial offices.*

- Energy: 0.4m tonnes CO₂e per annum
- HFA and manufacturing emissions: 0.25m tonnes CO₂e per annum
- Sales force: 0.05m tonnes CO₂e per annum

Logistics
Scope 3 emissions from delivering medicines and vaccines across the globe.

- Upstream logistics: 0.3m tonnes CO₂e per annum
- Downstream logistics: 0.1m tonnes CO₂e per annum
- Use of metered dose inhalers: 5.4m tonnes CO₂e per annum
- Use of other products: <0.1m tonnes CO₂e per annum

Patient use
Scope 3 emissions from patients using our products.

- Use of other products: <0.1m tonnes CO₂e per annum

Disposal
Scope 3 emissions from the disposal of our products by GSK patients.

- Upstream logistics: 0.3m tonnes CO₂e per annum

* Scope 1 and 2 market-based emissions
* based on data from 2022

March 2024
## Priority actions to reduce emissions

We are taking action to reduce emissions across our full value chain, prioritising the highest impact areas.

Beyond 2030 we expect we will be left with the harder to tackle emissions from across our supply chain, our own operations, logistics, and disposal. Addressing these residual emissions will in many cases be dependent on technologies, infrastructure and regulatory frameworks that will require broad public/private collaboration, and so our decarbonisation is interdependent and following a similar timeframe to the broader economic transition.

<table>
<thead>
<tr>
<th>Purchased goods and services</th>
<th>GSK’s operations</th>
<th>Logistics</th>
<th>Patient use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scope 3 emissions</strong></td>
<td><strong>Scopes 1 and 2 emissions</strong></td>
<td><strong>Scope 3 emissions</strong></td>
<td><strong>Scope 3 emissions</strong></td>
</tr>
<tr>
<td>31% 3.0m tonnes CO₂e per annum</td>
<td>7% 0.7m tonnes CO₂e per annum</td>
<td>4% 0.4m tonnes CO₂e per annum</td>
<td>57% 5.5m tonnes CO₂e per annum</td>
</tr>
</tbody>
</table>

**Purchased goods and services**
- Sustainable Procurement Programme, driving targeted supplier engagement and setting sustainability standards
- Deep engagement with 30 most impactful suppliers
- Peer collaboration through Energize programme to expand access to renewable electricity across our shared supply chains
- Manufacture 2030 helping with engagement, measurement and the development of emission reduction glidepaths for suppliers
- Activate programme with peers to reduce the environmental impact in Active Pharmaceutical Ingredient value chains
- Converge, a collaborative supply chain initiative by My Green Lab, to encourage suppliers to reduce the environmental impact of labs in the value chain

**GSK’s operations**
- Renewable electricity and heat
  - Members of RE100
  - Onsite production through wind turbines and solar panels, together with buying renewable electricity and through power purchase agreements
  - Developing renewable heat strategy
- Electric vehicles
  - Members of EV100
  - Committed to transition our sales fleet to low-carbon vehicles by 2030
  - Target to install charging infrastructure at 100 sites
- Energy reductions
  - Ongoing focus on energy efficiency programmes

**Logistics**
- Maximising transition from air freight to sea freight
- Ensuring full container optimization
- Sector peer collaboration to identify common logistic routes and to pilot ‘green corridors’

**Patient use**
- Predominantly from the propellant used in metered dose inhalers (MDIs) for asthma and chronic obstructive pulmonary disease
- Investing in a low-carbon programme and if successful, it has the potential to reduce greenhouse gas emissions from the inhaler by 90% by transitioning to a next generation, lower-carbon propellant. Phase III trials will begin in 2024 and, if successful, regulatory submissions will start in 2025
- Beyond MDIs, product stewardship programme to embed eco-design principles for all new products

---

Full carbon footprint includes 1% scope 3 emissions from the disposal of our products by GSK patients.
Our approach to carbon credits

Whilst we are focused on emissions reductions to meet our carbon targets, at the same time, we are investing in high quality nature protection and restoration projects that support our net-zero and nature positive goals, and deliver co-benefits to human health.

We plan to secure carbon credits for the 20% emissions we estimate to have as residual in 2030, and for a maximum of 10% residual emissions by 2045. We aim to secure all of the credits for the 2030 target through nature investments by 2028. These credits will be issued later in the decade and will be retired against our 2030 residual emissions and onwards, yearly.

For our 2030 target we are prioritizing carbon removal credits, but we will also secure a proportion of carbon avoidance and reductions credits in recognition of their critical role in conserving existing carbon stocks and protecting nature. For our 2045 Net Zero target, we will aim to only secure carbon removal credits.

We plan to secure carbon credits for the 20% emissions we estimate to have as residual in 2030, and for a maximum of 10% residual emissions by 2045.

Credit quality and integrity

We understand the scepticism around the quality of some of the existing carbon credits in the Voluntary Carbon Market (VCM). We aim to invest in high quality and high integrity projects:

- We partner with expert developers and NGOs to invest in early-stage projects for the long term and ensure the design is inclusive of nature and health co-benefits.
- We work with external experts to identify appropriate criteria for investments, covering carbon technical aspects (scientific verification, additionality, leakage, permanence etc) and other impacts (avoidance of harm, benefit-sharing mechanism, IPLC and vulnerable communities’ co-benefits, scientific innovation, etc).
- We work with multiple partners to run extensive due diligence on projects before investments.
- We continue to review evolving and emerging guidance documents, including those provided by the Voluntary Carbon Market Initiative and Science Based Targets Initiative, to ensure we are aligned with leading experts guiding the use of carbon credits.
- In partnership with Pollination, and with input from key nature and health experts from organisations such as the Circular Bioeconomy Alliance, the Nature Climate Solutions Alliance and the London School of Hygiene and Tropical Medicine we have published an open-source toolkit to support companies, investors and developers to incorporate health considerations in the design of nature-based projects.
- We are open to co-investment opportunities if they increase the scale of the potential impact on the ground and reduce the risks, intrinsic in nature projects.

Current projects in our portfolio

GSK is an investor in Climate Asset Management’s Nature Based Carbon Fund, which aims to invest at a landscape scale in grassland, agriculture, forestry, wetlands and coastal carbon projects in developing economies, to provide long-lasting, verified, positive impact at scale for the climate, biodiversity and local communities. This is a long-term investment over the next 15 years, which aims to secure approximately a quarter of credits that we need in 2030, to meet our commitment to invest in nature-based solutions for 20% of our 2020 footprint.

We are part of the LEAF coalition (Lowering Emissions by Accelerating Forest finance), a private-public effort to protect tropical forests.

We recognise that this is a fast-moving space, and that methodologies and guidelines will likely evolve as we implement our plans.

We commit to remaining flexible and transparent about our progress and learning.
Our pathway to net zero

The graph below shows our projected carbon reduction pathway to 2030 and 2045 across the different parts of our carbon footprint, along with our planned carbon credits.

**Climate targets**
- Pathway

**Carbon footprint**
- 2020–22
- Reported data

**Reduction priorities**
- Ongoing investment in nature projects to build credit portfolio
- Patient use/Disposal: scope 3 emissions
- Purchased goods and services/Logistics: scope 3 emissions
- GSK’s operations: scope 1 and 2 emissions

**Approach to carbon credits**
- Retirement of removal, reduction and avoidance credits
- Retirement of removal credits only
- SBTI 1.5°C pathway

**Ongoing investment in nature projects**
- To build credit portfolio

**2025**
- Target 100% renewable electricity at sites

**2030**
- Aiming for 80% emission reductions

**2045**
- Target for Net Zero impact on climate, with carbon emissions reduced by at least 90%

**Carbon credits for**
- 20% residual emissions
- A maximum of 10% residual emissions
Annual progress against these targets is published in the ESG Performance report.
ESG resources | GSK

Our TCFD disclosure is published in the Annual Report.
Financial reports | GSK

More information about our approach to sustainability is on our website here:
Environmental sustainability | GSK